SCHEMBL5145149

SCHEMBL5145149

CN1C(=O)S/C(=C/c2ccc(-c3ccc(C(=O)O)c(Cl)c3)o2)C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.68
▸ MEN1 O00255 6/20 0.68
▸ TDP1 Q9NUW8 6/20 0.68
▸ POLB P06746 5/20 0.68
▸ L3MBTL1 Q9Y468 4/20 0.68
▸ CTDSP1 Q9GZU7 2/20 0.68
▸ NPC1 O15118 2/20 0.65
▸ RAB9A P51151 2/20 0.65
▸ CASP3 P42574 1/20 0.59
▸ SENP8 Q96LD8 1/20 0.59
▸ SENP7 Q9BQF6 1/20 0.59
▸ SENP6 Q9GZR1 1/20 0.59
▸ PTPN22 Q9Y2R2 3/20 0.56
▸ KEAP1 Q14145 2/20 0.55
▸ NFE2L2 Q16236 2/20 0.55
▸ TTR P02766 1/20 0.54
▸ MAP3K5 Q99683 1/20 0.54
▸ MAPT P10636 4/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ KDM4E B2RXH2 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145153 1.00 KMT2A (0.68) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL6389826 0.83 MEN1 (0.70) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL6390413 0.83 MEN1 (0.84) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL6390408 0.83 MEN1 (0.84) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL6389833 0.83 MEN1 (0.70) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL5147227 0.81 MEN1 (1.00) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL5147232 0.81 MEN1 (1.00) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL12177529 0.81 ALDH1A1 (0.59) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL12177382 0.81 POLB (0.66) KMT2AMEN1TDP1POLBL3MBTL1
SCHEMBL29757941 0.79 SLC1A3 (0.70) KMT2AMEN1TDP1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 — — EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 — — EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 — — US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KMT2A 4410/4885MEN1 4004/4885TDP1 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback